Sacred Geometry

Category: Uncategorized

  • Anthony Holland’s RF Plasma Experiments: The Cells, the Frequencies, and the Evidence

    Anthony Holland’s RF Plasma Experiments: The Cells, the Frequencies, and the Evidence

    Conceptual RF plasma research setup with a microscope, cell culture, signal equipment, and glowing enclosed-gas plasma tube
    Conceptual illustration of an RF plasma cell-culture experiment—not a photograph of Holland’s apparatus.

    Anthony Holland’s RF-plasma experiments occupy an unusual place in the history of bioelectromagnetics. The work began far outside conventional oncology, reached a real university cancer laboratory, produced recorded and sometimes quantified effects in cultured human cancer cells, and then ran directly into the standard that separates an arresting observation from a proven treatment: controls, replication, peer review, and eventually clinical testing.

    This is the story of what Holland and his collaborators actually built, what they reported seeing under the microscope, what later experiments measured—and what the evidence still does not establish.

    Research context: Every result discussed here was produced in cell culture. Holland’s RF-plasma approach has not been established as safe or effective for treating cancer in people. Nothing in this article is medical advice, and none of the RF/plasma equipment sold by Sacred Geometry is a medical device.

    From frequency synthesis to an enclosed-gas plasma antenna

    Holland was a longtime Skidmore College music professor, orchestra conductor, composer, and specialist in digital audio synthesis. His central technical idea was not that audible music would kill cancer. He used programmable waveforms to control an RF transmitter and power amplifier, which in turn energized a sealed, gas-filled glass tube. The glowing plasma tube acted as an antenna for an oscillating, pulsed electric field.

    The later papers call this oscillating pulsed electric fields, or OPEF. A typical research chain consisted of a programmable frequency source, amplitude modulation, an RF carrier, a high-power RF amplifier, an impedance tuner, and an enclosed helium plasma tube positioned near a cell culture. The pulse-repetition or modulation frequency was varied while the RF carrier and plasma assembly delivered the field.

    That distinction matters. This was not a loudspeaker experiment, and it was not simply “playing a frequency” into a room. It was an RF electronics platform whose visible plasma tube served as the radiating element.

    A genuine university-laboratory test

    Holland’s work did enter a mainstream academic research setting. Skidmore’s 2008–2009 Faculty Development Committee report records his project as collaborative research and experimentation on human cancer cells at Thomas Jefferson University Medical College in Philadelphia. Cancer researcher Jonathan Brody supervised the work in his laboratory.

    The laboratory was not a staged demonstration. It had cell incubators, tissue-culture facilities, microscopes, prepared cancer cell lines, and the ability to count treated and control cells. Holland worked through long overnight sessions, moving cultures from the incubator to the microscope stage, exposing them to selected frequencies, recording time-lapse images, and comparing the outcomes with untreated cultures.

    An early pancreatic-cancer experiment looked dramatic: the reported survival was about 10% in a pulsed group receiving a small amount of chemotherapy versus about 60% in the comparison group. But the treated and control plates had not experienced the same time outside the incubator. Brody correctly treated that run as invalid rather than as proof.

    Later leukemia observations were more encouraging. Contemporary reporting described roughly 30% greater cell death in a pulsed group than in controls. Yet a later pancreatic run moved in the opposite direction: the pulsed cells appeared more resistant to the chemotherapy. Brody’s conclusion was the scientific one—the work had to be repeated with tighter controls before it could support publication or a medical claim.

    That mixed record does not erase the observations. It defines them accurately. Holland showed that his apparatus could be tested in a real cancer-research laboratory and that measurable differences sometimes appeared between exposed and comparison cultures. The Thomas Jefferson collaboration did not produce a replicated, peer-reviewed demonstration of a cancer treatment.

    What the microscope recordings documented

    A 2012 conference-proceedings paper by Gérard Dubost, Anthony Holland, James Bare, and Frederic Bellossi described the experimental arrangement in more detail. Human cancer cells in 96-well plates were placed on an inverted research microscope with a high-resolution video camera. The plasma-tube electrodes were approximately 45 centimeters from the cells.

    The authors reported time-correlated changes in cell morphology—including fragmentation and, in some recorded cases, apparent disintegration—while leukemia, pancreatic, and ovarian cell cultures were exposed to particular pulsed-field settings. The paper lists examples including K562 leukemia cells around 197 kHz, pancreatic cell lines in the 150–162 kHz region, and ovarian cells exposed at 114 and 150 kHz, using RF power in roughly the 250–325 watt range.

    The significance of the recordings is straightforward but limited: they preserve a real-time visual observation rather than relying only on memory or a before-and-after photograph. Video can show when a cell changes shape or fragments. It cannot, by itself, establish the cause, rule out heating or handling effects, prove selectivity for malignant cells, or demonstrate that the same event can occur safely inside a living person.

    The proposed mechanism centered on structures involved in cell division—especially microtubules, the mitotic spindle, and later the actomyosin cortex. The hypothesis was that a frequency and field-strength “window” could mechanically destabilize dividing cells. It remains a hypothesis for this particular plasma-broadcast method, not a settled biological mechanism.

    The later leukemia measurements

    At the 2015 BioEM meeting, Holland presented the work as in vitro and explicitly “work in progress.” The conference abstract reported cell fragmentation and inhibited proliferation in two human leukemia cell lines after exposure to frequency-specific, amplitude-modulated RF pulsed plasma fields.

    The most detailed later dataset appeared in a 2023 bioRxiv preprint by Holland and Bare. Acute lymphocytic leukemia cells (Coriell catalog GM03638) were exposed to a 160 kHz pulse-repetition signal broadcast from an enclosed helium plasma antenna approximately 18 inches away. The described hardware used a 27.12 MHz RF carrier and a 300-watt amplifier. Cells received nine hours of exposure per day for three days, followed by 48 hours of incubation and a Trypan Blue viability assay.

    Across five reported OPEF experiments, the authors calculated growth-rate reductions of 24% to 44%, averaging 38%, compared with five control experiments. They reported a p-value of 0.0053. Those figures are the clearest quantitative result in Holland’s published record.

    They should still be read as preliminary. The paper is a preprint and was not certified by peer review. Its controls were run before the five exposure experiments rather than concurrently in a randomized, blinded design. The paper does not establish human dosing, tissue penetration, whole-body safety, healthy-cell selectivity, or clinical benefit. Independent replication under a preregistered protocol would be the next meaningful evidentiary step.

    What was demonstrated—and what was not

    The strongest responsible summary is this:

    • Demonstrated in a laboratory: A programmable RF/plasma apparatus was operated near cultured human cancer cells in academic and research settings. Investigators recorded cell morphology in real time, and several experiments reported inhibited proliferation or increased cell loss at selected settings.
    • Documented beyond a talk: The work appears in a Skidmore research record, international workshop proceedings, a BioEM conference program, recorded interviews from the Thomas Jefferson collaboration, and a later bioRxiv preprint with methods and numerical results.
    • Not demonstrated: A cure, a clinically validated cancer treatment, safe exposure parameters for people, reliable tumor selectivity, or independent reproducibility of the complete OPEF protocol.

    That boundary is not a dismissal. It is the exact point at which an intriguing bench result becomes a serious research program—or fails to survive one.

    The broader electric-field context

    Frequency-specific electric fields are not inherently outside modern medicine. Tumor Treating Fields (TTFields) use insulated electrode arrays to deliver low-intensity, intermediate-frequency alternating electric fields. FDA-reviewed TTFields systems have clinical indications for several cancers, including glioblastoma, and the FDA approved an abdominal TTFields system for locally advanced pancreatic cancer in 2026.

    That clinical history is relevant because it confirms that carefully engineered electric fields can interact with dividing cells in medically useful ways. It does not validate Holland’s plasma-antenna delivery method. TTFields use different hardware, field geometry, dosimetry, treatment protocols, safety testing, and clinical evidence. Similar scientific vocabulary is not interchangeable proof.

    The RF/plasma research architecture in our shop

    Sacred Geometry carries experimental equipment in the same general RF/plasma hardware lineage described in Holland’s work: programmable frequency generation, RF power stages, tuning and control components, and enclosed-gas plasma tubes.

    Our 310 kHz High-Power OPEF Generator System is a Plasma Sonics-derived, 300-watt research platform built around the same broad architecture, and our plasma-tube collection includes compatible experimental antenna geometries. We also carry a 190-watt plasma amplifier for compatible bench systems.

    These products are offered for experimental, engineering, or agricultural research and personal frequency exploration. They are not FDA-cleared medical devices, are not sold to diagnose or treat disease, and should not be substituted for oncology care. Owning similar hardware does not reproduce Holland’s protocol or his reported observations; controlled methods, measurement, shielding, field characterization, and safety procedures are part of the experiment.

    The value of Holland’s work

    Holland’s most durable contribution may be neither the sweeping claims made by admirers nor the blanket dismissal made by critics. It is the decision to bring an unconventional apparatus into a laboratory where cells could be cultured, recorded, counted, challenged with controls, and—when the result reversed—questioned.

    The recorded cell fragmentation and later leukemia growth-inhibition data are legitimate reasons for further investigation. They are not the final word. Good experimental science begins when the remarkable observation survives the next laboratory, the next operator, the next control, and eventually the clinical trial.

    Sources and further reading

    This article is educational and historical. It does not provide medical advice or recommend any experimental device for medical use. Anyone facing cancer should work with a qualified oncology team and should not delay or replace evidence-based care.

  • From Fringe to FDA: How Electromagnetic Field Therapy Entered Mainstream Medicine

    Electromagnetic field therapy spent a long time filed under “alternative medicine,” and in most contexts, it still is. But if you trace the actual FDA clearance history, a different picture shows up: real hospitals, real surgeons, and real oncologists have been using purpose-built electromagnetic and magnetic field devices for decades, in increasingly serious clinical contexts. Here’s the timeline, told straight, including where the categories genuinely differ from each other.

    1979: Bones

    The starting point. Following C. Andrew Bassett’s Columbia University research on inducing bone growth with pulsed magnetic fields, the FDA cleared the first PEMF bone growth stimulator for non-union fractures — breaks that had stalled and stopped healing naturally. That’s still an active clinical use today, and it later expanded into adjunctive support for cervical spinal fusion surgery.

    2008: Post-surgical recovery

    Nearly thirty years later, the same underlying technology — pulsed electromagnetic fields, at low intensity — got a second, distinct FDA clearance: SofPulse, cleared in December 2008 for adjunctive palliative treatment of postoperative pain and edema in superficial soft tissue. This is the clearance most directly relevant to recovery-focused wellness use, since it’s specifically about swelling and pain reduction rather than driving new bone growth.

    2008: The brain (a different technology, same broad family)

    Also in 2008, the FDA cleared Transcranial Magnetic Stimulation (TMS) for treatment-resistant major depressive disorder. It’s important to be precise here: TMS is not PEMF. It uses focused, high-intensity magnetic pulses aimed at a specific brain region (usually the left dorsolateral prefrontal cortex) under clinical supervision, at parameters well outside what a wellness-oriented PEMF device produces. General PEMF is not FDA-cleared for depression, and the evidence there is still preliminary. What TMS does demonstrate is that the broader category — using magnetic pulses to influence biological tissue — had, by 2008, become serious enough to clear the bar for treating a major psychiatric condition, not just orthopedic injury.

    Today: Cancer, and a real (if different) frequency neighbor

    This brings us to Novocure’s Optune, and it’s worth being exact about what it is and isn’t. Optune delivers Tumor Treating Fields (TTFields) — low-intensity, intermediate-frequency alternating electric fields (not pulsed magnetic fields) delivered through adhesive scalp arrays. The mechanism is specific to actively dividing cells: TTFields disrupt the formation of the mitotic spindle and cause dielectrophoresis effects during cell division, which interferes with cancer cells’ ability to divide. It’s FDA-approved as a treatment for glioblastoma, one of the most aggressive brain cancers there is, and has shown real survival benefit in clinical trials.

    TTFields and PEMF are genuinely different technologies — electric field vs. magnetic field, continuous alternating vs. pulsed, ~200 kHz vs. the much lower frequencies most PEMF devices operate at. We’re not going to pretend Optune validates PEMF wellness devices, because it doesn’t. What is genuinely interesting is a detail that’s shown up in the research literature: osteogenic PEMF (the bone-healing frequency band) sits in a kHz range that happens to be close to Optune’s operating frequency, which has prompted some early-stage researchers to investigate whether PEMF might have any anti-cancer relevance of its own. That’s a real research thread — and it’s explicitly early, exploratory, and not something anyone should read as an established claim.

    What the arc actually shows

    Zoom out, and the pattern isn’t “one company proved electromagnetic therapy works.” It’s that four separate, independently-evaluated device categories — bone stimulators, post-surgical recovery devices, TMS, and TTFields — each went through FDA review, on their own evidence, for their own specific condition, across a 45-year span. That’s a meaningfully different story than “alternative medicine,” and it’s the actual reason PEMF technology is worth taking seriously as a category.

    It’s also exactly why we’re careful about what we claim for our own products. Sacred Geometry sells wellness and hobbyist PEMF devices, not any of the FDA-cleared medical devices described above. None of what’s above is a claim about what our devices do — it’s the honest context for why the underlying technology has a legitimate research foundation, which is different from a guarantee about any specific consumer product.

  • Frequency Healing 101: What the Research Actually Shows

    Once you start looking into PEMF, you run into two very different worlds of “frequency” information at the same time: peer-reviewed research measuring specific Hz ranges against specific outcomes, and centuries-old traditions (Solfeggio tones, the Schumann resonance) that treat frequency as symbolically or energetically significant. Both show up constantly in PEMF marketing, usually blended together without a label. We think that’s a disservice — so here’s each, kept separate, with sources.

    What clinical research has actually measured

    Bone healing: ~1.5–75 Hz, with 15 Hz as the clinical standard

    This is the best-established range in the literature, for the obvious reason that it’s the oldest and most-studied application. A 2025 review of bone and cartilage response to PEMF found effective stimulation broadly across roughly 1.5–75 Hz, and most FDA-cleared bone growth stimulators specifically use 15 Hz. Intensity matters here too — research generally places bone-healing protocols in a medium intensity range (roughly 15–30 Gauss), notably higher than the pain/inflammation range below.

    Pain and inflammation: lower intensity, broader frequency band

    The pain research is the deepest evidence base after bone healing. A 2013 Cochrane review found moderate-quality evidence for reduced pain and improved function in knee osteoarthritis. A 2015 meta-analysis in Clinical Rheumatology, pooling 15 trials and over 1,000 patients, found a statistically significant pain-score reduction versus sham treatment. A 2019 randomized trial published in PLOS One found a 25% greater reduction in fibromyalgia pain intensity compared to sham. More recent systematic reviews have specifically examined soft tissue injuries and non-specific low back pain. Across this body of work, lower intensity (roughly 1–10 Gauss) shows up more often than the higher intensities used for bone, and the proposed mechanism is downregulation of inflammatory signaling (the NF-κB and MAPK pathways specifically) rather than a single “magic” frequency.

    Sleep and relaxation: 1–4 Hz (preliminary)

    This is the least mature area of the three. Some research has looked at very low frequencies — roughly 1–3 Hz, in the same range as delta brainwave activity (0.5–4 Hz, associated with deep sleep and cellular recovery) — for sleep-related outcomes. We want to be honest that this is a thinner, more preliminary evidence base than bone healing or pain, closer to “promising and worth more research” than “established.”

    Muscle relaxation: ~15–30 Hz

    A secondary thread in the literature places muscle-relaxation-focused protocols in roughly the same mid-range used for bone healing, which tracks with the broader pattern that mid frequencies (roughly 10–30 Hz) tend to dominate musculoskeletal applications generally, while the lowest frequencies (under ~4 Hz) cluster around nervous-system/sleep-adjacent research instead.

    What’s tradition, not clinical research

    Separately from all of the above, the wellness and sound-healing communities have their own long-standing frequency frameworks — most commonly the Solfeggio frequencies (a set of tones, like 396 Hz or 528 Hz, tied to a modern reconstruction of medieval Gregorian chant scales) and the Schumann resonance (Earth’s own electromagnetic resonance, centered around 7.83 Hz, which is a real, measurable geophysical phenomenon, even though the specific health claims built around it go well beyond what’s been measured). These frameworks are meaningful to a lot of people, and there’s nothing wrong with exploring them — but they come from tradition and numerology, not the clinical literature above, and we’re not going to blur that line by presenting them as if a study measured them. If you’re drawn to that side of frequency work, the SG102’s full range covers it too; just know what you’re standing on when you use it.

    How this maps onto the SG102

    The SG102 is fully adjustable across 1 Hz–150 kHz with independent duty-cycle (intensity) control from 0–100% on three parallel channels — which means the entire researched range above (roughly 1–75 Hz for the clinical literature, and up through the low kHz range if you want to explore the traditional frequency systems) is available to experiment with on one unit, alongside room to go well beyond it if you’re doing your own research.

    Before you start

    A few real, sourced contraindications worth taking seriously: anyone with a pacemaker, defibrillator, insulin pump, cochlear implant, or other implanted electronic device should not use PEMF due to interference risk. It’s considered an absolute contraindication during pregnancy (insufficient safety data on fetal development). And if you have epilepsy or another seizure disorder, active cancer, or a bleeding disorder, talk to a specialist before using any electromagnetic device — magnetic stimulation carries a theoretical effect on seizure threshold that’s worth a real conversation with your doctor, not a guess.

    None of this is medical advice, and none of it is a claim that the SG102 or any Sacred Geometry product diagnoses, treats, cures, or prevents any disease. It’s a summary of where the actual research stands, so you can make an informed decision about your own experimentation.

  • What Is PEMF Therapy? The Science Behind Pulsed Electromagnetic Fields

    “PEMF” gets thrown around a lot in wellness circles, often next to language that makes it sound like folklore. It isn’t. Pulsed electromagnetic field technology has a real, documented, 50-year paper trail in mainstream medicine — it’s just narrower and more specific than most marketing copy admits. Here’s what’s actually established, and where the line sits between “clinically proven” and “worth experimenting with.”

    The basic physics

    A PEMF device runs current through a coil in short pulses. Each pulse generates a brief magnetic field, and as that field rises and falls, it induces a small electrical current in whatever tissue sits inside it — the same principle (electromagnetic induction, per Faraday’s law) that runs a transformer. This is the key thing that separates PEMF from a static magnet: a static magnet just sits there with a fixed field, while a pulsed field is actively inducing current the whole time it’s cycling. That induced current is the mechanism everything downstream depends on.

    Where it started

    The modern research trail starts with C. Andrew L. Bassett and Arthur Pawluk at Columbia University, who published foundational work in Science in 1974 showing that pulsed electromagnetic fields could stimulate new bone formation (osteogenesis) in non-healing fractures. That research led directly to the first FDA premarket approval for a PEMF device in 1979 — the Biomet EBI Bone Healing System (originally marketed as the Bio-Osteogen System 204) — cleared specifically for non-union fractures: breaks that had stopped healing on their own. That clearance has held for over four decades and PEMF bone stimulators are still prescribed today.

    What’s happened since

    From that starting point, the clinical footprint expanded into a few specific, well-defined areas:

    • Adjunctive spinal fusion — PEMF stimulators are used alongside cervical fusion surgery to support bone growth at the fusion site, the same underlying mechanism as the original fracture clearance.
    • Post-surgical pain and edema — devices like SofPulse (Endonovo Therapeutics) received FDA clearance in December 2008 specifically for adjunctive palliative treatment of postoperative pain and swelling in superficial soft tissue, backed by five published clinical studies.
    • Soft tissue and joint pain — a 2013 Cochrane review found moderate-quality evidence that PEMF reduced pain and improved function in knee osteoarthritis, and more recent systematic reviews have looked specifically at soft tissue injuries and non-specific low back pain, both finding meaningful (if not universally consistent) benefit across the trials reviewed.

    What the mechanism research suggests

    The “why” is still an active research area, but the leading thread is inflammation regulation: several studies have found that PEMF exposure downregulates pro-inflammatory signaling (specifically the NF-κB and MAPK pathways) and shifts cytokine levels toward anti-inflammatory mediators, in both in-vitro and in-vivo work. That’s a plausible biological explanation for why a technology discovered for bone healing also shows up in pain and soft-tissue-injury research — inflammation control is relevant to all three.

    Where consumer devices fit in

    It’s worth being direct about this: the FDA clearances above are for specific, purpose-built medical devices, used under specific protocols, for specific diagnosed conditions. A consumer PEMF device — including the ones we sell — is not one of those devices, hasn’t gone through that regulatory process, and isn’t intended to diagnose, treat, cure, or prevent any disease. What you’re getting is the same underlying technology (a coil, a pulse generator, an adjustable field) in a form built for personal experimentation rather than clinical use. The research above is real, and it’s the reason this technology has our attention — but it describes the medical devices it was conducted on, not a guarantee about any specific consumer product.

    If you’re on any medication, have an implanted electronic device (pacemaker, insulin pump, neurostimulator), are pregnant, or have a seizure disorder, talk to a doctor before using any PEMF device, consumer or otherwise.